MaxCyte, Washington University in St. Louis announce collaboration

MaxCyte Inc. and Washington University in St. Louis announced a collaboration to develop unique immunotherapy drug candidates based on MaxCyte’s proprietary cell engineering platform technology, CARMA.

CARMA allows simple and rapid manufacture of advanced cancer treatments that utilize a patient’s own immune system and is differentiated from traditional CAR therapy due to its use of mRNA to engineer immune cells delivered back into a patient. By utilizing transient expression via mRNA delivery, CARMA allows control over severe adverse effects, opening the high potency of CAR immunotherapies to a broader range of cancers than traditional CAR approaches.

John DiPersio, chief of the Division of Oncology at Washington University School of Medicine and deputy director of the Siteman Cancer Center, and members of his team will collaborate with MaxCyte to conduct preclinical research with a focus on developing a potential investigational CAR therapy targeting acute myeloid leukemia and other related blood cancers. Financial terms were not disclosed.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast The Directors

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri

As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.

October 16, 2026

Vol.52 No.38

By Sara Willa Ernst and Paul Goldberg

Conversation with The Cancer Letter

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

October 16, 2026

Vol.52 No.38

By Claire Marie Porter and Paul Goldberg

Obituary

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

Rachna Shroff, a physician-scientist who spent much of her career researching treatments for pancreatic and biliary cancers, has died at the age of 47. She briefly battled an aggressive cancer of an unknown origin.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

News Analysis

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Pope Leo XIV has been diagnosed with lung adenocarcinoma. According to missives from the Holy See, the pope underwent surgery to remove the lower lobe of his right lung Oct. 13.

October 16, 2026

Vol.52 No.38

By Jacquelyn Cobb

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

A Fox Chase Cancer Center team is combining a rare longitudinal family cohort, whole-genome sequencing, AI-guided analysis, and laboratory validation to investigate why people with similar inherited susceptibility can experience very different cancer outcomes.

October 16, 2026

Vol.52 No.38

By Fox Chase Cancer Center

Cancer Policy

Letai announces: NCI met FY26 goal of full funding payout

In a post on NCI’s LinkedIn, NCI Director Anthony Letai confirmed that the institute has fully awarded and paid out all of its grant funding for the Fiscal Year 2026.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

MaxCyte, Washington University in St. Louis announce collaboration

YOU MAY BE INTERESTED IN

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

Letai announces: NCI met FY26 goal of full funding payout

Renew today!

Subscriber content

Never miss an issue!

Login

MaxCyte, Washington University in St. Louis announce collaboration

YOU MAY BE INTERESTED IN

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDsCenter directors are strategizing for likely FDA approval of GRAIL’s Galleri

As trust in USPSTF erodes, cancer screening is in perilDavid Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47Her endowed award will live on

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

Letai announces: NCI met FY26 goal of full funding payout

Never miss an issue!

Login

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”